FDA To Review Pfizer’s Abrilada For Humira Interchangeability

Adalimumab Biosimilar Is Set For US Launch In July 2023

The US FDA is reviewing Pfizer’s Humira biosimilar, Abrilada, to assess whether the compound can be granted an interchangeability designation with the original drug.

Signpost two directions
Pfizer is seeking an interchangeable designation for its adalimumab biosimilar • Source: Frannyanne / Alamy Stock Photo

After announcing plans for the filing as it reported its Q3 results last year, Pfizer’s Abrilada (adalimumab-afzb) is now one step closer to being classed as an interchangeable biosimilar with AbbVie’s Humira (adalimumab), following the US Food and Drug Administration’s acceptance for review of the prior approval supplement to the biologics license application for the compound.

The PAS was supported by positive topline data from Pfizer’s REFLECTIONS B538-12 study, which evaluated multiple switches between Abrilada and...

Welcome to Generics Bulletin

Create an account to read this article

More from Biosimilars

Regulatory Recap: FDA Starts ‘Radical Transparency’ Era After Publishing Over 200 CRLs

 

Generics Bulletin reviews global regulatory developments across the world.

Industry Welcomes Support From UK Life Sciences Plan

 
• By 

A new life sciences strategy unveiled by the UK government has won plaudits from the off-patent industry for its inclusion of measures specifically geared towards generics and biosimilars – especially a £1bn savings target linked to biosimilar uptake.

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By 

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.

More from Products

FTC’s Latest Effort To Dispute Improper Patent Listings Barely Made A Dent

 

Trump’s FTC has carried on two legacies – trying to eliminate improper drug patent listings and making minimal impact on such efforts.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By 

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By 

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.